INTRODUCTION
Philadelphia-negative acute lymphoblastic leukemia (Ph-neg ALL) refers to the vast majority of adult patients with acute lymphoblastic leukemia (ALL; 60%-85%). 1 Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered a standard of care for those achieving first hematological remission (first complete remission [CR1]) but presenting with high-risk features such as persistent minimal residual disease and poor-risk cytogenetics. 2, 3 Recent data from the European Society for Blood and Marrow Transplantation (EBMT) indicate that the results of allo-SCT for adults with ALL improved significantly over time during the last 20-year period. 4 However, the procedure is still associated with a considerable risk of complications, among which acute graft-versus-host disease (aGVHD) and chronic graftversus-host disease (cGVHD) are the leading causes of transplant-related morbidity and mortality. 5 Furthermore, cGVHD affects up to 80% of long-term transplant survivors and results in an increased risk of infections, multiorgan dysfunction, prolonged administration of immunosuppressive drugs, and impaired quality of life. 6, 7 During the last decade, mobilized peripheral blood stem cells (PBSCs) have become the predominant source of grafts for allo-SCT in adults. 5, 8 In comparison with bone marrow transplantation, PBSC transplantation allows significantly faster neutrophil and platelet engraftment, but it is associated with an increased risk of overall and extensive cGVHD. 6 It results most likely from the higher content of donor T cells in PBSC grafts, which play a pivotal role in the pathogenesis of graft-versus-host reactions. Anti-thymocyte globulins (ATGs) are polyclonal immunoglobulin G used for the in vivo T-cell depletion of grafts. The addition of ATG to the conditioning regimen may reduce the incidence of graft-versus-host disease (GVHD) but is associated with delayed immune reconstitution. As a result, it may potentially result in an increased risk of infections and an increased risk of leukemia relapse. 9 Data reported so far regarding the use of ATG in patients undergoing allo-SCT from both human leukocyte antigen-matched sibling and unrelated donors with myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) indicate that ATG may provide a benefit, especially in terms of reducing the incidence of cGVHD. 9 However, the prospective, randomized studies published so far have included heterogeneous patient populations, with the vast majority diagnosed with myeloid malignancies. [10] [11] [12] [13] [14] The available data for patients with Phneg ALL is rather limited. Although the effect on GVHD may be uniform, regardless of the diagnosis, the impact on the risk of relapse may depend on the type of underlying malignancy. Therefore, the goal of this EBMT registry-based, retrospective study was to analyze the effect of ATG on the outcome of allogeneic peripheral blood stem cell transplantation (allo-PBSCT) for adult patients with Ph-neg ALL.
MATERIALS AND METHODS

Study Design and Data Retrieval
Data for this retrospective study were provided by the Acute Leukemia Working Party of the EBMT registry. The study was approved by the institutional review board of the Acute Leukemia Working Party of the EBMT. The EBMT is a voluntary working group of more than 500 transplant centers that are required to report all consecutive stem cell transplants and follow-ups once a year. Audits are routinely performed to determine the accuracy of the data. The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Since 1990, all patients have provided informed consent authorizing the use of their personal information for research purposes.
Criteria of Selection
The inclusion criteria were set as follows: 1) a patient with Ph-neg ALL in CR1 who underwent his or her first allo-SCT between January 2007 and December 2016, 2) an age 18 years, 3) a transplant from a human leukocyte antigen-matched sibling donor (MSD) or human leukocyte antigen-matched (8 of 8 loci) unrelated donor (MUD), and 4) the use of PBSCs as a source of stem cells. Transplants with in vivo T-cell depletion using agents other than ATG and those with ex vivo T-cell depletion were excluded from the analysis. The use of posttransplant cyclophosphamide for GVHD prevention was also an exclusion criterion.
Statistical Analysis
The primary endpoint of the study was graft-versus-host disease-free/relapse-free survival (GRFS), which was defined as a composite endpoint of GVHD-free survival and relapse-free survival after allo-SCT; events included grade 3 to 4 aGVHD, cGVHD, relapse, and death from any cause (whichever occurred first). The secondary outcome measures were 1) the incidence of grade 2 to 4 and grade 3 to 4 aGVHD, 2) the incidence of overall and extensive cGVHD, 3) nonrelapse mortality (NRM), 4) the relapse incidence (RI), 5) the probability of leukemiafree survival (LFS), and 6) overall survival (OS). Patients' characteristics were compared with the Kruskal-Wallis test for numerical variables and with the chi-square test for categorical variables. Cumulative incidence functions were used to estimate the probabilities for aGVHD, cGVHD, RI, and NRM in a competing risk setting. 15 To study aGVHD and cGVHD, we considered relapse and death to be competing events. Probabilities of OS and LFS were calculated with the Kaplan-Meier estimates. 16 Univariate analyses were performed with log-rank tests for LFS and OS, whereas Gray's test was used for cumulative incidence functions. A Cox proportional hazards model was used for multivariate regression. 17 All variables differing significantly between the 2 groups or factors known to influence outcomes were included in the Cox model. The median follow-up for survivors was 24 and 25 months for patients in the ATG and no-ATG groups, respectively. All tests were 2-sided with a type I error rate fixed at .05. Analyses were run on the entire population and then stratified by donor type (MSD vs MUD). Statistical analyses were performed with SPSS 22.0 (IBM Corp, Armonk, New York) and R 3.2.3 5 (R Foundation for Statistical Computing, Vienna, Austria; https://www.R-project.org/).
RESULTS
Patients, Donors, and Allo-SCT Procedure
A total of 924 patients, aged 18 to 72 years, were included in the analysis; 404 of these patients received ATG as part of their pretransplant conditioning. ATG was used in 97 of the 494 transplants from MSDs (20%) and in 307 of the 430 transplants from MUDs (71%). The conditioning regimen was myeloablative for 766 of the allo-SCT cases (83%). Table 1 summarizes patients' characteristics, focusing on the use of ATG. Patients in the ATG group were significantly older, had a longer median interval from diagnosis to transplantation, were more frequently given transplants from MUDs and from female donors to male recipients, more frequently had donors with a negative cytomegalovirus (CMV) serological status, and were less frequently treated with myeloablative and total body irradiation-based conditioning regimens.
Impact of ATG on the Engraftment and GVHD
The engraftment rate was not affected by the use of ATG and equaled 99% in both groups. The time to neutrophil engraftment was delayed for those who received ATG (median, 18 days; range, 8-56 days) in comparison with the no-ATG group (median, 14 days; range, 5-45 days; P < 10
24
). In a univariate analysis, the use of ATG was associated with a decreased incidence of both overall cGVHD and extensive cGVHD ( Table 2 and Fig. 1 ). In contrast, no impact could be demonstrated with respect to the incidence of grade 2 to 4 and grade 3 to 4 aGVHD ( ), and extensive cGVHD (HR, 0.30; P < 10
25
; Table 3 ). In addition, allo-PBSCT from MUDs versus MSDs was associated with an increased risk of grade 2 to 4 and grade 3 to 4 aGVHD. The risk of both overall and extensive cGVHD was increased for transplants from female donors to male recipients. Detailed results of the multivariate analyses are summarized in Table 3 .
In subgroup analyses stratified by donor type, among recipients of allo-PBSCT from MSDs, the administration of ATG resulted in a reduction of the risk of both overall cGVHD (HR, 0.38; P 5 .0008) and extensive cGVHD (HR, 0.17; P 5 .0003). Similar associations with respect to the incidence of overall (HR, 0.46; P 5 .00003) and extensive cGVHD (HR, 0.35; P 5 .00003) were found in recipients of allo-PBSCT from MUDs. Furthermore, in the case of ATG use, the risk of grade 2 to 4 aGVHD (HR, 0.53; P 5 .0001) and grade 3 to 4 aGVHD (HR, 0.49; P 5 .0001) was reduced for those who received transplants from MUDs.
Impact of ATG on GRFS
In a univariate analysis, the use of ATG was associated with an increased probability of GRFS (Table 2 and Fig. 2). The favorable effect of ATG on GRFS was confirmed in a multivariate model (HR, 0.70; P 5 .0009; Table 3 ). Other factors that were found to influence GRFS were allo-PBSCT with RIC versus MAC and a positive recipient CMV serological status (Table 3) .
In a separate subgroup analysis focusing on the donor type, we demonstrated an increased chance of GRFS for patients receiving ATG with allo-PBSCT from MSDs (HR, 0.64; P 5 .01) and MUDs (HR, 0.72; P 5 .02).
Impact of ATG on NRM
In a multivariate model, the use of ATG was found to be associated with a significant reduction of the risk of NRM (HR, 0.58; P 5 .01; Table 3 and Fig. 3A ). In addition, the risk of NRM increased with increasing patient age and with allo-PBSCT from MUDs versus MSDs (Table 3) .
The most frequent causes of NRM in the ATG group were infections (40%) and GVHD (36%), whereas in the no-ATG group, the predominant causes of NRM were GVHD (46%) and infections (26%).
Impact of ATG on the Incidence of Disease Recurrence
Within the entire study cohort, the use of ATG was associated with an increased risk of relapse in a multivariate model (HR, 1.40; P 5 .04; Table 3 and Fig. 3B ). Among other potential risk factors, RIC regimens were associated with a significantly increased risk of relapse in comparison with MAC regimens, whereas the RI was decreased for allo-PBSCT performed from MUDs versus MSDs (Table 3) . In a subgroup analysis, among recipients of allo-PBSCT from MUDs, the risk of relapse was increased for patients treated with ATG (HR, 1.79; P 5 .04). Among recipients of allo-PBSCT from MSDs, such an adverse effect of ATG use was not noted. Donor lymphocyte infusions were used in 8% and 11% of the patients to treat relapse after allo-SCT in in the ATG and no-ATG groups, respectively. Allo-SCT was performed for a second time in 20% and 12% of cases, respectively. 
Impact of ATG on Survival
The probabilities of LFS and OS did not differ between patients who received ATG and patients who did not receive ATG (Table 2 and Fig. 4) . In a multivariate analysis, the risk of treatment failure (either relapse or NRM) increased with increasing recipient age, with RIC regimens versus MAC regimens, and with a positive recipient CMV serological status. Finally, the risk of overall mortality increased with increasing recipient age (Table 3) .
DISCUSSION
In this retrospective study including a large homogeneous cohort of 924 patients with Ph-neg ALL in CR1, we have demonstrated the beneficial effect of the addition of ATG to the conditioning regimen before allo-PBSCT in terms of an increased chance of survival free from GVHD and relapse. Furthermore, the administration of ATG resulted in a reduced risk of grade 2 to 4 and grade 3 to 4 aGVHD and also overall and extensive cGVHD. The probability of NRM decreased in the ATG group. However, its use was associated with a significantly increased risk of relapse. As a result, the probabilities of LFS and OS were superimposable.
Five randomized studies have addressed the impact of ATG on the results of allo-SCT, mainly in patients with acute myeloid leukemia (AML). Four of the studies included unrelated donors. [10] [11] [12] [13] [14] 18 The first study by Bacigalupo et al 10 focused only on bone marrow as a source of stem cells. Finke et al 11 reported in turn on 201 patients assigned to the administration of ATG Fresenius/Neovii (ATG-F) at a total dose of 60 mg/kg or a placebo added to MAC before allo-PBSCT (82%) or allogeneic bone marrow transplantation. Although the study included both AML and ALL, most of the patients were diagnosed with AML. At 100 days, the cumulative incidence of grade 2 to 4 aGVHD was lower in the ATG-F group versus the group of patients who did not receive ATG-F. Recently, the authors published updated results of this study with a median follow-up of 8.6 years. At 8 years, the incidence of extensive cGVHD was significantly reduced in the ATG-F group, whereas the probabilities of both GRFS and being alive and free from immunosuppressive therapy were increased among patients treated with ATG-F. No significant impact of ATG-F on RI, NRM, LFS, or OS was noted. 12 In the study by Walker et al, 13 196 patients were randomly assigned to receive a total of 4.5 mg/kg of Thymoglobuline (ATG-T) or a placebo. The conditioning regimen was MAC in two-thirds of the cases. PBSCs were used as a graft source for 88% of the transplants. Again, only a minority of patients were diagnosed with ALL (15%). The incidences of aGVHD and severe cGVHD were lower in the ATG-T study arm, and the probability of being free from immunosuppressive treatment at 12 months was higher in the ATG-T group versus the placebo group. NRM, RI, and survival did not differ between the ATG-T and control study arms. The only trial focusing on allo-PBSCT from MSDs, by Kroger et al, 14 demonstrated in 155 patients (two-thirds of them with the diagnosis of AML) that the administration of ATG-F (total dose, 30 mg/kg) resulted in a reduced Abbreviations: aGVHD, acute graft-versus-host disease; allo-SCT, allogeneic hematopoietic stem cell transplantation; ATG, anti-thymocyte globulin; cGVHD, chronic graft-versus-host disease; CI, confidence interval; CMV, cytomegalovirus; GRFS, graft-versus-host disease-free/relapse-free survival; LFS, leukemia-free survival; MAC, myeloablative conditioning; MSD, human leukocyte antigen-matched sibling donor; MUD, human leukocyte antigen-matched (8 of 8 loci) unrelated donor; NRM, nonrelapse mortality; OS, overall survival; RI, relapse incidence; RIC, reduced-intensity conditioning. All the following factors were included in the multivariate analyses: ATG vs no ATG, MUD versus MSD, age (per 10 years), year of allo-SCT, time from diagnosis to allo-SCT, female donor to male recipient, RIC versus MAC, CMV-positive serostatus for the patient, and CMV-positive serostatus for the donor. This table presents only the influence of ATG use and factors with a significant impact (P <.05). Bolded values are significant.
incidence of both limited and extensive cGVHD and led to a higher probability of GRFS. RI, NRM, and survival were not affected by the use of ATG-F. Soiffer et al 18 recently presented the results of a study that included 254 patients, mostly with AML or myelodysplastic syndromes, in which ATG-F (60 mg/kg total) was added to MAC before allo-PBSCT (80%) or allogeneic bone marrow transplantation from MUDs. The incidences of grade 2 to 4 aGVHD and moderate/severe cGVHD were lower in the ATG-F arm. However, both OS and PFS at 2 years were significantly decreased in the ATG-F group, partly because of the increased RI.
In the current analysis, we have focused solely on adult patients with ALL, who have been underrepresented in randomized clinical trials. Furthermore, we have restricted the analysis to Ph-neg ALL because modern treatment protocols for patients with the presence of the Philadelphia chromosome differ considerably. 19 We have chosen only PBSCs as a source of grafts because of their predominant use and association with an increased risk of cGVHD, which provides a strong rationale for the administration of ATG. 5, 6, 8 In this homogeneous population of patients with Ph-neg ALL, we were able to demonstrate the beneficial role of ATG in terms of reducing the risk of aGVHD and cGVHD and increasing the probability of GRFS. Importantly, the effect on cGVHD could be demonstrated, regardless of the donor type. The reduction of the cGVHD rate translated into a reduced risk of NRM, mainly because of fewer GVHDrelated deaths among patients treated with ATG, whereas Figure 2 . Impact of ATG on the probability of survival free from relapse, grade 3 to 4 acute graft-versus-host disease, and chronic graft-versus-host disease (GRFS; P Cox 5 .0009). ATG indicates anti-thymocyte globulin; GRFS, graft-versus-host disease-free/ relapse-free survival.
the infection rate was higher. Indeed, previous reports also indicated higher rates of infections, particularly viral infections (Epstein-Barr virus and CMV) associated with the use of ATG. [10] [11] [12] [13] [14] 18 Disease recurrence is the major cause of treatment failure in adults with ALL treated with allo-SCT. It has been demonstrated that in ALL the risk of relapse is strongly associated with the incidence of cGVHD, and this indicates the relevance of a graft-versus-leukemia reaction accompanying cGVHD. 4 Therefore, it could be speculated that by the reduction of the cGVHD rate caused by the administration of ATG, the risk of relapse may be increased. On the other hand, it may be hypothesized that ATG itself provides some activity against ALL cells. The drug is a mixture of polyclonal antibodies with many specificities. Target antigens are present not only on mature T cells but also on T-and B-cell progenitors. [20] [21] [22] [23] Indeed, it has been previously demonstrated that the administration of ATG provides some direct antineoplastic activity, mainly against lymphoid malignancies, including ALL. [24] [25] [26] The results of our analyses indicate, however, that the negative effect of the use of ATG on immune-related graft-versus-leukemia reactions predominates and results in an increased risk of relapse.
Our study has some limitations related to its retrospective nature. In particular, data on the ATG brand as well as the details of ATG administration with respect to the total dose and timing were unavailable for the majority of patients. Therefore, these variables could not be included in the analysis. However, we can confirm that that according to the EBMT registry data, all patients included in the study received rabbit ATG. As reflected in turn by the survey performed by the EBMT, the 2 ATG formulations most commonly used in the European centers are ATG-T and ATG-F. The median reported total dose of ATG-T was 7.5 mg/kg (range, 4-32 mg/kg), whereas the total doses of ATG-F were 30 (30%) and 60 mg/kg (19%) with a range of 1.5 to 75 mg/kg. 27 The third ATG formulation, which is horse (equine)-derived, is not available in Europe; however, it is still used in the United States for in vivo T-cell depletion in the context of allo-SCT. The 2 types of rabbit ATG differ in terms of antigen specificity, with a wider spectrum documented for ATG-T than ATG-F. Rabbit ATG, in comparison with the horse formulation, is in turn associated with more effective lymphocyte depletion and enhancement of the number and function of regulatory T cells. 28, 29 The beneficial effect of the addition of a rabbit formulation instead of the horse formulation of ATG to the conditioning regimen before allogeneic bone marrow transplantation for severe aplastic anemia on clinical outcomes, including GVHD, was recently demonstrated. 29, 30 All the aforementioned differences may influence both immunosuppressive and potential antileukemic properties of the drug and indicate that the 3 available ATG formulations should not be considered interchangeable agents. Furthermore, ATG-related immune effects may depend on dosing and also timing (ie, the interval from drug infusion to allo-SCT). Earlier administration provides more effect on host T cells and, therefore, reduces the risk of graft failure, whereas later infusions provide interactions mainly with donor-derived T cells and influence more strongly the risk of GVHD. The impact of the different ATG dosing on the clinical outcomes of allo-SCT was apparent in previously quoted randomized trials and was recently proved in a direct randomized comparison of 15 and 30 mg/kg ATG-F administrated before unrelated donor allo-SCT in a population of children with hematologic malignancies. The lower dose was associated with a significantly decreased risk of NRM and an increased probability of LFS. 31 Nevertheless, on the basis of the results of the current analysis, we conclude that patients with Ph-neg ALL treated with allo-PBSCT benefit from the use ATG in terms of survival free from GVHD and relapse. Although the use of ATG is not associated with prolonged OS, it significantly reduces the incidence of aGVHD, cGVHD, and NRM, and this is of major clinical benefit. Further studies are needed to determine the optimal dosage and timing of ATG for patients with Ph-neg ALL to elucidate the maximum benefit coming from the reduction of GVHD-related morbidity and mortality while avoiding an increased risk of relapse.
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